Market revenue in 2023 | USD 167.6 million |
Market revenue in 2030 | USD 228.8 million |
Growth rate | 4.5% (CAGR from 2023 to 2030) |
Largest segment | Porcine |
Fastest growing segment | Bovine |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Porcine, Bovine |
Key market players worldwide | Pfizer Inc, Sanofi SA, Aspen Pharmacare Holdings Ltd, Fresenius SE & Co KGaA, Novartis AG ADR, GSK PLC ADR, Dr. Reddy’s Laboratories, LEO Pharma, B. Braun Medical |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to heparin market will help companies and investors design strategic landscapes.
Porcine was the largest segment with a revenue share of 89.08% in 2023. Horizon Databook has segmented the South Korea heparin market based on porcine, bovine covering the revenue growth of each sub-segment from 2018 to 2030.
Market growth in South Korea is driven by increasing prevalence of chronic diseases, such as hypertension and hyperlipidemia. According to the NCBI, the prevalence of hypertension was approximately 30% from 2010 to 2015, which is a large number of patients prone to heart disease.
South Korea has the highest prevalence of 7.6% in Asia. According to the World Bank, in 2018, the geriatric population of South Korea was 7,445,058, a demographic that is at a high risk of stroke. It is also expected the prevalence and burden of chronic diseases will continue to increase due to the increase in elderly population.
Heparin is successfully being used during plasma exchange of anaphylaxis patients. Growing awareness about chronic diseases is expected to further boost market share. However, as per Journal of Stroke, in 2019, stroke has been the second-most prevalent cause of death in South Korea, but only 10.7% of ischemic stroke patients receive thrombolytic therapies such as heparin.
Horizon Databook provides a detailed overview of country-level data and insights on the South Korea heparin market , including forecasts for subscribers. This country databook contains high-level insights into South Korea heparin market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account